These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9861918)

  • 1. Budesonide substitution in Crohn's disease relieves CNS toxicity of systemic steroids.
    Thomas MC; Schlup MM
    Med J Aust; 1998 Nov; 169(10):560. PubMed ID: 9861918
    [No Abstract]   [Full Text] [Related]  

  • 2. Budesonide modified-release capsules.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Brief: Extended-release budesonide (Ortikos) for Crohn's disease.
    Med Lett Drugs Ther; 2020 Nov; 62(1610):176. PubMed ID: 33429405
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children.
    Levine A; Broide E; Stein M; Bujanover Y; Weizman Z; Dinari G; Pacht A; Branski D; Zahavi I
    J Pediatr; 2002 Jan; 140(1):75-80. PubMed ID: 11815767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral budesonide approved for active Crohn's disease.
    Thompson CA
    Am J Health Syst Pharm; 2001 Dec; 58(23):2229. PubMed ID: 11763799
    [No Abstract]   [Full Text] [Related]  

  • 6. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
    Rutgeerts P
    Gut; 1999 Jul; 45(1):13-4. PubMed ID: 10498451
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
    Rutgeerts P
    Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide in the treatment of Crohn's disease: a meta-analysis.
    Papi C; Luchetti R; Gili L; Montanti S; Koch M; Capurso L
    Aliment Pharmacol Ther; 2000 Nov; 14(11):1419-28. PubMed ID: 11069312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budesonide for induction of remission in Crohn's disease.
    Otley A; Steinhart AH
    Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Crohn's disease at the turn of the century.
    Bickston SJ; Cominelli F
    N Engl J Med; 1998 Aug; 339(6):401-2. PubMed ID: 9691110
    [No Abstract]   [Full Text] [Related]  

  • 11. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
    Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
    Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of joint pain in Crohn's patients with budesonide controlled ileal release.
    Florin TH; Graffner H; Nilsson LG; Persson T
    Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):295-8. PubMed ID: 10779128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of long-term budesonide treatment in maintaining remission in patients with mild-to-moderate Crohn's disease.
    Tursi A; Giorgetti GM; Brandimarte G; Elisei W
    Inflamm Bowel Dis; 2007 Sep; 13(9):1184-6. PubMed ID: 17410564
    [No Abstract]   [Full Text] [Related]  

  • 14. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy.
    Cino M; Greenberg GR
    Am J Gastroenterol; 2002 Apr; 97(4):915-21. PubMed ID: 12003427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease.
    Levine A; Weizman Z; Broide E; Shamir R; Shaoul R; Pacht A; Dinari G; On A; Weiss B; Bujanover Y;
    J Pediatr Gastroenterol Nutr; 2003 Feb; 36(2):248-52. PubMed ID: 12548062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.
    Bar-Meir S; Chowers Y; Lavy A; Abramovitch D; Sternberg A; Leichtmann G; Reshef R; Odes S; Moshkovitz M; Bruck R; Eliakim R; Maoz E; Mittmann U
    Gastroenterology; 1998 Oct; 115(4):835-40. PubMed ID: 9753485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease.
    Abreu MT
    Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):210-1. PubMed ID: 16265201
    [No Abstract]   [Full Text] [Related]  

  • 19. Budesonide: its role in Crohn's disease therapy.
    Coleman CI; Reddy P; White CM
    Conn Med; 2002 Sep; 66(9):523-6. PubMed ID: 12369546
    [No Abstract]   [Full Text] [Related]  

  • 20. Budesonide for Crohn's disease.
    Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.